Mercedes Salgado
Overview
Explore the profile of Mercedes Salgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trujillo-Santos J, Garcia-Escobar I, Salgado M, Araujo A, Martinez-de-Castro E, Molina R, et al.
Oncologist
. 2024 Dec;
PMID: 39673414
Background: Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can...
2.
Escobar Y, Ramchandani A, Salgado M, Castillo-Trujillo A, de Castro E, Diaz de Corcuera I, et al.
Clin Transl Oncol
. 2023 Jun;
25(12):3479-3491.
PMID: 37289352
Introduction: Cancer patients often suffer from malnutrition and early detection and raising awareness of nutritional issues is crucial in this population. Methods: The Spanish Oncology Society (SEOM) conducted the Quasar_SEOM...
3.
Munoz A, Ay C, Grilz E, Lopez S, Font C, Pachon V, et al.
J Clin Oncol
. 2023 Feb;
41(16):2911-2925.
PMID: 36730884
Purpose: Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving...
4.
Valladares-Ayerbes M, Garcia-Alfonso P, Munoz Luengo J, Pimentel Caceres P, Castillo Trujillo O, Vidal-Tocino R, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551560
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA (/) mutational status...
5.
Alves J, Estevez-Gomez N, Valecha M, Prado-Lopez S, Tomas L, Alvarino P, et al.
Genomics
. 2022 Oct;
114(6):110500.
PMID: 36202322
The genomic profiling of circulating tumor cells (CTCs) in the bloodstream should provide clinically relevant information on therapeutic efficacy and help predict cancer survival. Here, we contrasted the genomic profiles...
6.
Salgado M, Brozos-Vazquez E, Campos B, Gonzalez-Villarroel P, Perez M, Vazquez-Tunas M, et al.
Clin Appl Thromb Hemost
. 2022 May;
28:10760296221098717.
PMID: 35538861
This article seeks to review the current status of treatment and prevention of venous thromboembolic disease (VTE) in cancer patients after the addition of direct oral anticoagulants (DOAC) to the...
7.
Mlakar I, Lin S, Nateqi J, Gruarin S, Dieguez L, Piairo P, et al.
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407649
(1) Background: The needs of cancer survivors are often not reflected in practice. One of the main barriers of the use of patient-reported outcomes is associated with data collection and...
8.
Elez E, Gomez-Espana M, Gravalos C, Garcia-Alfonso P, Ortiz-Morales M, Losa F, et al.
Br J Cancer
. 2021 Dec;
126(6):874-880.
PMID: 34937947
Background: Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the...
9.
Mlakar I, Lin S, Aleksandravica I, Arcimovica K, Eglitis J, Leja M, et al.
BMC Med Inform Decis Mak
. 2021 Aug;
21(1):243.
PMID: 34391413
Background: It is encouraging to see a substantial increase in individuals surviving cancer. Even more so since most of them will have a positive effect on society by returning to...
10.
Vera R, Gomez M, Ayuso J, Figueras J, Garcia-Alfonso P, Martinez V, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32806731
: The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after...